<DOC>
	<DOCNO>NCT00000865</DOCNO>
	<brief_summary>To assess steady state pharmacokinetic feature , tolerance , safety orally administer 1592U89 , give alone combination antiretroviral medication , HIV infect infant child . To establish dos 1592U89 appropriate future pediatric Phase II/III clinical trial . On basis preclinical clinical study , 1592U89 appear promising agent treatment HIV infection child , either alternative currently employ agent , combination therapy regimens . A liquid formulation drug available ; thus concurrent development 1592U89 child adult possible .</brief_summary>
	<brief_title>The Safety Effects 1592U89 Used Alone Combination With Other Anti-HIV Drugs HIV-Infected Infants Children</brief_title>
	<detailed_description>On basis preclinical clinical study , 1592U89 appear promising agent treatment HIV infection child , either alternative currently employ agent , combination therapy regimens . A liquid formulation drug available ; thus concurrent development 1592U89 child adult possible . In part 1 , patient receive 1592U89 monotherapy 12 week . Patients assign initially low dose 1592U89 ( Dose A ) . Those patient tolerate drug least six week without toxicity grade 3 attributable study drug 1592U89 dose increase ( Dose B ) . If none patient experience life threaten event attributable study drug , subsequent enrollee assign initially Dose B . In part 2 , participant assign randomly ( 1:1:1:1 ) within age Part 1 regimen stratum one four agent : Zidovudine ( ZDV ) , Stavudine ( d4T ) , Didanosine ( ddI ) Lamivudine ( 3TC ) combination 1592U89 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : IVIG . Erythropoietin , granulocyte colony stimulate factor granulocyte macrophage colony stimulate factor ( management hematologic toxicity ) . Patients must : Documented HIV1 infection . Laboratory evidence immunosuppression symptomatic HIV disease . Parent legal guardian able willing provide sign informed consent . Prior Medication : Required : HIV infect infant child eligible trial receive great 56 day previous antiretroviral therapy . NOTE : Those child participate single dose phase I study 1592U89 satisfy criterion inclusion may receive &lt; = 56 day previous antiretroviral therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Grade 3 great abnormality toxicity monitor laboratory test baseline . Presence acute opportunistic infection require therapy time enrollment . Intractable chronic diarrhea vomit . Concurrent Medication : Excluded : Chemotherapy active malignancy . Concurrent use antiretroviral agent provide study , biologic response modifier , human growth hormone , systemic corticosteroid ( &gt; = 14 day duration ) , probenecid , I.V . pentamidine , immunomodulators ( intravenous immunoglobulin ) , investigational drug . Patients follow prior condition symptom exclude : History intolerance study drug .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>